5/15/2025

Janusmed sex and gender

Janusmed sex and gender – cinacalcet hydrochloride

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Cinacalcet

Cinacalcet

Class : C

Show all info

Print

Contact us

  1. Mimpara (cinakalcet). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2017-04-09, cited 2019-07-22]

  2. US Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].

  3. Mimpara (cinakalcet) EPAR Scientific discussion. European Medicines Agency (EMA) [updated 2005-10-21, cited 2019-05-28]

  4. Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism. 2008;57(4):517-21.

  5. US Food and Drug Administration. Statistical review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].

  6. US Food and Drug Administration. Medical review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].

  7. Otsuka K, Ohno Y, Oshima J. Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Ren Fail. 2018;40(1):38-42.

  8. US National Library of Medicine. Sensipar (cinacalcet). DailyMed [www]. [updated 2012-05-01, cited 2019-07-22].

  9. Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol. 2015;10(5):800-7.

  10. Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R et al. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015;26(6):1466-75.

  11. Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab. 2013;98(12):4834-44.

  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]

  1. Mimpara (cinakalcet). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2017-04-09, cited 2019-07-22]
  2. US Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].
  3. Mimpara (cinakalcet) EPAR Scientific discussion. European Medicines Agency (EMA) [updated 2005-10-21, cited 2019-05-28]
  4. Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism. 2008;57(4):517-21.
  5. US Food and Drug Administration. Statistical review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].
  6. US Food and Drug Administration. Medical review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].
  7. Otsuka K, Ohno Y, Oshima J. Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Ren Fail. 2018;40(1):38-42.
  8. US National Library of Medicine. Sensipar (cinacalcet). DailyMed [www]. [updated 2012-05-01, cited 2019-07-22].
  9. Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol. 2015;10(5):800-7.
  10. Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R et al. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015;26(6):1466-75.
  11. Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab. 2013;98(12):4834-44.
  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]